Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

Q2 Medicine

Oncotarget Pub Date : 2025-03-12 DOI:10.18632/oncotarget.28703

Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon, Jeremy L Warner, Stephanie L Graff, Christopher G Azzoli, Eric T Wong, Liang Cheng, Sendurai A Mani, Howard P Safran, Casey Williams, Tobias Meissner, Benjamin Solomon, Eitan Rubin, Angel Porgador, Guy Berchem, Pierre Saintigny, Amir Onn, Jair Bar, Raanan Berger, Manon Gantenbein, Zhen Chen, Cristiano de Pádua Souza, Rui Manuel Vieira Reis, Marina Sekacheva, Andrés Cervantes, William L Dahut, Christina M Annunziata, Kerri Gober, Khaled M Musallam, Humaid O Al-Shamsi, Ibrahim Abu-Gheida, Ramon Salazar, Sewanti Limaye, Adel T Aref, Roger R Reddel, Mohammed Ussama Al Homsi, Abdul Rouf, Said Dermime, Jassim Al Suwaidi, Catalin Vlad, Rares Buiga, Amal Al Omari, Hikmat Abdel-Razeq, Luis F Oñate-Ocaña, Finn Cilius Nielsen, Leah Graham, Jens Rueter, Anthony M Joshua, Eugenia Girda, Steven Libutti, Gregory Riedlinger, Mohammed E Salem, Carol J Farhangfar, Ruben A Mesa, Bishoy M Faltas, Olivier Elemento, C S Pramesh, Manju Sengar, Satoru Aoyama, Sadakatsu Ikeda, Ioana Berindan-Neagoe, Himabindu Gaddipati, Mandar Kulkarni, Elisabeth Auzias, Maria Gerogianni, Nicolas Wolikow, Simon Istolainen, Pessie Schlafrig, Naftali Z Frankel, Amanda R Ferraro, Jim Palma, Alejandro Piris Gimenez, Alberto Hernando-Calvo, Enriqueta Felip, Apostolia M Tsimberidou, Roy S Herbst, Josep Tabernero, Richard L Schilsky, Jia Liu, Yves Lussier, Jacques Raynaud, Gerald Batist, Shai Magidi, Razelle Kurzrock

{"title":"Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.","authors":"Wafik S El-Deiry, Catherine Bresson, Fanny Wunder, Benedito A Carneiro, Don S Dizon, Jeremy L Warner, Stephanie L Graff, Christopher G Azzoli, Eric T Wong, Liang Cheng, Sendurai A Mani, Howard P Safran, Casey Williams, Tobias Meissner, Benjamin Solomon, Eitan Rubin, Angel Porgador, Guy Berchem, Pierre Saintigny, Amir Onn, Jair Bar, Raanan Berger, Manon Gantenbein, Zhen Chen, Cristiano de Pádua Souza, Rui Manuel Vieira Reis, Marina Sekacheva, Andrés Cervantes, William L Dahut, Christina M Annunziata, Kerri Gober, Khaled M Musallam, Humaid O Al-Shamsi, Ibrahim Abu-Gheida, Ramon Salazar, Sewanti Limaye, Adel T Aref, Roger R Reddel, Mohammed Ussama Al Homsi, Abdul Rouf, Said Dermime, Jassim Al Suwaidi, Catalin Vlad, Rares Buiga, Amal Al Omari, Hikmat Abdel-Razeq, Luis F Oñate-Ocaña, Finn Cilius Nielsen, Leah Graham, Jens Rueter, Anthony M Joshua, Eugenia Girda, Steven Libutti, Gregory Riedlinger, Mohammed E Salem, Carol J Farhangfar, Ruben A Mesa, Bishoy M Faltas, Olivier Elemento, C S Pramesh, Manju Sengar, Satoru Aoyama, Sadakatsu Ikeda, Ioana Berindan-Neagoe, Himabindu Gaddipati, Mandar Kulkarni, Elisabeth Auzias, Maria Gerogianni, Nicolas Wolikow, Simon Istolainen, Pessie Schlafrig, Naftali Z Frankel, Amanda R Ferraro, Jim Palma, Alejandro Piris Gimenez, Alberto Hernando-Calvo, Enriqueta Felip, Apostolia M Tsimberidou, Roy S Herbst, Josep Tabernero, Richard L Schilsky, Jia Liu, Yves Lussier, Jacques Raynaud, Gerald Batist, Shai Magidi, Razelle Kurzrock","doi":"10.18632/oncotarget.28703","DOIUrl":null,"url":null,"abstract":"<p><p>The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.</p>","PeriodicalId":19499,"journal":{"name":"Oncotarget","volume":"16 ","pages":"140-162"},"PeriodicalIF":0.0000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11907938/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncotarget","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.18632/oncotarget.28703","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

The human genome project ushered in a genomic medicine era that was largely unimaginable three decades ago. Discoveries of druggable cancer drivers enabled biomarker-driven gene- and immune-targeted therapy and transformed cancer treatment. Minimizing treatment not expected to benefit, and toxicity-including financial and time-are important goals of modern oncology. The Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine founded by Drs. John Mendelsohn and Thomas Tursz provided a vision for innovation, collaboration and global impact in precision oncology. Through pursuit of transcriptomic signatures, artificial intelligence (AI) algorithms, global precision cancer medicine clinical trials and input from an international Molecular Tumor Board (MTB), WIN has led the way in demonstrating patient benefit from precision-therapeutics through N-of-1 molecularly-driven studies. WIN Next-Generation Precision Oncology (WINGPO) trials are being developed in the neoadjuvant, adjuvant or metastatic settings, incorporate real-world data, digital pathology, and advanced algorithms to guide MTB prioritization of therapy combinations for a diverse global population. WIN has pursued combinations that target multiple drivers/hallmarks of cancer in individual patients. WIN continues to be impactful through collaboration with industry, government, sponsors, funders, academic and community centers, patient advocates, and other stakeholders to tackle challenges including drug access, costs, regulatory barriers, and patient support. WIN's collaborative next generation of precision oncology trials will guide treatment selection for patients with advanced cancers through MTB and AI algorithms based on serial liquid and tissue biopsies and exploratory omics including transcriptomics, proteomics, metabolomics and functional precision medicine. Our vision is to accelerate the future of precision oncology care.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊